Lv5
1540 积分 2024-05-20 加入
AI3 Disease-Free Survival (DFS) As a Surrogate Endpoint for Overall Survival (OS) in Adults with Resectable Esophageal or Gastroesophageal Junction Cancer: A Correlation Meta-Analysis
3小时前
待确认
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
3小时前
待确认
Abstract P2-12-09: Correlation between pathologic complete response (pCR), event-free survival (EFS)/disease-free survival (DFS) and overall survival (OS) in neoadjuvant and/or adjuvant (NAdj/Adj) hormone receptor positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC)
5天前
已完结
A weighted combined effect measure for the analysis of a composite time‐to‐first‐event endpoint with components of different clinical relevance
5天前
已完结
Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis
5天前
已完结
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
5天前
已完结
Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
1个月前
已完结
Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
1个月前
已关闭
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
3个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3个月前
已完结
皖公网安备34019202002308
